Atara Biotherapeutics, Inc. (ATRA): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$50.94M

Year ended 2025-12-31

2013-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$50.94M	n/m	2026-03-16, From 2025-01-01
2024-12-31	-$68.96M	n/m	2026-03-16, From 2024-01-01
2023-12-31	-$194.20M	n/m	2025-03-07, From 2023-01-01
2022-12-31	-$274.62M	n/m	2024-03-28, From 2022-01-01
2021-12-31	-$231.10M	n/m	2023-02-08, From 2021-01-01
2020-12-31	-$185.27M	n/m	2023-02-08, From 2020-01-01
2019-12-31	-$241.36M	n/m	2022-02-28, From 2019-01-01
2018-12-31	-$215.70M	n/m	2021-03-01, From 2018-01-01
2017-12-31	-$107.73M	n/m	2020-02-27, From 2017-01-01
2016-12-31	-$63.05M	n/m	2019-02-26, From 2016-01-01
2015-12-31	-$37.45M	n/m	2018-02-27, From 2015-01-01
2014-12-31	-$16.67M	n/m	2017-03-09, From 2014-01-01
2013-12-31	-$5.97M	n/a	2016-03-04, From 2013-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Atara Biotherapeutics, Inc. (ATRA)	2025-12-31	-$50.94M	n/m
Monte Rosa Therapeutics, Inc. (GLUE)	2025-12-31	-$27.50M	n/m
Agenus Inc (AGEN)	2025-12-31	-$77.20M	n/m
ImmunityBio, Inc. (IBRX)	2025-12-31	-$308.78M	n/m
Century Therapeutics, Inc. (IPSC)	2025-12-31	-$104.72M	n/m
Beam Therapeutics Inc. (BEAM)	2025-12-31	-$360.05M	n/m
Ginkgo Bioworks Holdings, Inc. (DNA)	2025-12-31	-$178.72M	n/m
REGENXBIO Inc. (RGNX)	2025-12-31	-$126.38M	n/m
4D Molecular Therapeutics, Inc. (FDMT)	2025-12-31	-$109.62M	n/m

Compare ATRA, GLUE, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗